Rezpegaldesleukin
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Rezpegaldesleukin
- il 2 peg conjugate nktr 358
- Il-2 peg conjugate (nktr-358)
- INTERLEUKIN 2 (DE-1-ALANINE,125-SERINE) (RECOMBINANT HUMAN), N6-(4-(2-((((2-HYDROXYETHYL)AMINO)CARBONYL)OXY)-1-(((((2-HYDROXYETHYL)AMINO)CARBONYL)OXY) METHYL)ETHOXY)-1-OXOBUTYL)-L-LYSINE DIETHER WITH .ALPHA.-HYDRO-.OMEGA.-METHOXYPOLY(OXY-1,2-ETHANEDIYL)
- interleukin 2 de 1 alanine 125 serine recombinant human n6 4 2 2 hydroxyethyl amino carbonyl oxy 1 2 hydroxyethyl amino carbonyl oxy methyl ethoxy 1 oxobutyl l lysine diether with alpha hydro omega methoxypoly oxy 1 2 ethanediyl
- ly 3471851
- LY-3471851
- ly3471851
- LY3471851
- nktr 358
- NKTR-358
- rezpegaldesleukin
- Rezpegaldesleukin
- rezpegaldesleukin [INN]
- REZPEGALDESLEUKIN [USAN]
- Rezpegaldesleukin [WHO-DD]
- rezpegaldesleukin inn
- rezpegaldesleukin usan
- rezpegaldesleukin who dd
- rezpegaldesleukina
- Rezpegaldesleukina
- rezpegaldesleukine
- Rezpegaldesleukine
- CAS registry numbers
- 2641686-76-0
- ChEMBL ID
- CHEMBL5095458
- FDA ingredient codes (UNII)
- VGR86P26ER
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -kin; -peg-
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Psoriasis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Alopecia Areata
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004192
- Subject identifier
- D000506
- Condition
- Autoimmune Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005809
- Subject identifier
- D001327
- Condition
- Lupus Erythematosus, Systemic
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007915
- Subject identifier
- D008180
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004192
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005809
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005083
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005147
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005340
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007179
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 2
- NCT03556007
- NCT04119557
- NCT04677179
- NCT06136741
- NCT06340360
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Sequence
- Type
- Protein
- Sequence
- PTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFSQSIISTLT
- Component
- Disulfide bridges
- Sequence
- 57-104
Related records
Trials (14)
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
- A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
- A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
- A Phase I Study of LY3471851 in Healthy Participants
- A Single-Dose Study of LY3471851 in Healthy Participants
- A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
- A Study of LY3471851 in Healthy Participants
- A Study of LY3471851 in Participants With Eczema
- A Study of LY3471851 in Participants With Psoriasis
- A Study of NKTR-358 (LY3471851) in Healthy Participants
- A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)
- Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
In development for (7)
- Alopecia areata Phase 2
- Atopic eczema Phase 2
- Autoimmune disease Phase 1
- Psoriasis Phase 1
- Systemic lupus erythematosus Phase 1
- Type 1 diabetes mellitus Phase 2
- Ulcerative colitis Phase 2